Quantifying patient preferences for treatments for refractory chronic spontaneous urticaria
Background: In recent years, it has become increasingly common to incorporate the patient perspective into drug development and regulatory decision making. Objective: This study aimed to measure and quantify patient preferences (priorities and trade-offs) for attributes that characterize current and...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-08-01
|
| Series: | Journal of Allergy and Clinical Immunology: Global |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772829325000694 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849343715083026432 |
|---|---|
| author | Olufemi Babalola, MHS, MSc, PhD Richard Hass, PhD John McAna, PhD Manav Segal, MD Juan Marcos Gonzalez, PhD Olajumoke Fadugba, MD |
| author_facet | Olufemi Babalola, MHS, MSc, PhD Richard Hass, PhD John McAna, PhD Manav Segal, MD Juan Marcos Gonzalez, PhD Olajumoke Fadugba, MD |
| author_sort | Olufemi Babalola, MHS, MSc, PhD |
| collection | DOAJ |
| description | Background: In recent years, it has become increasingly common to incorporate the patient perspective into drug development and regulatory decision making. Objective: This study aimed to measure and quantify patient preferences (priorities and trade-offs) for attributes that characterize current and emerging refractory chronic spontaneous urticaria (rCSU) treatments. Methods: Adult patients with self-reported rCSU symptoms completed an online discrete choice experiment survey. The survey included 10 questions that asked respondents to choose between 2 hypothetical rCSU treatment profiles having similar attributes with varying levels. The attributes included the following: chance of control of symptoms, time to symptom control, return of symptoms after discontinuation of therapy (complete remission), allergic reaction, risk of kidney dysfunction (usually reversible), and mode and frequency of administration. Relative attribute importance and maximum acceptable risks were calculated. Results: A total of 213 subjects with a mean age of 51 years completed the survey. Efficacy (symptom control) and mode of administration were the 2 most important attributes to treatment choice, followed by risk of kidney dysfunction and time to achieve symptom control. Complete remission of symptoms and risk of allergic reaction were identified as least important. With regard to mode of administration, topical treatment was the most preferred option and infusion therapy was least preferred. Respondents who were presented with a scenario of refractory and severe chronic spontaneous urticaria were willing to accept increased risk of reversible kidney dysfunction in exchange for improvement in symptom control or complete remission. Respondents were willing to accept infusion over topical treatment if there was significant increase in treatment efficacy. Conclusion: These study results can be used to inform development and evaluation of future rCSU therapies by product developers and regulatory authorities, respectively. |
| format | Article |
| id | doaj-art-5334e8fb5f2e474e82dd016212c57fe4 |
| institution | Kabale University |
| issn | 2772-8293 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Allergy and Clinical Immunology: Global |
| spelling | doaj-art-5334e8fb5f2e474e82dd016212c57fe42025-08-20T03:42:53ZengElsevierJournal of Allergy and Clinical Immunology: Global2772-82932025-08-014310046810.1016/j.jacig.2025.100468Quantifying patient preferences for treatments for refractory chronic spontaneous urticariaOlufemi Babalola, MHS, MSc, PhD0Richard Hass, PhD1John McAna, PhD2Manav Segal, MD3Juan Marcos Gonzalez, PhD4Olajumoke Fadugba, MD5Jefferson College of Population Health, Thomas Jefferson University, Philadelphia, PaJefferson College of Population Health, Thomas Jefferson University, Philadelphia, PaJefferson College of Population Health, Thomas Jefferson University, Philadelphia, PaChestnut Hill Allergy and Asthma Associates, Wyndmoor, PaDepartment of Population Health Sciences, Duke University, Durham, NCSection of Allergy and Immunology, Division of Pulmonary, Allergy and Critical Care Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa; Corresponding author: Olajumoke O. Fadugba, MD, 3737 Market St, Philadelphia, PA 19104.Background: In recent years, it has become increasingly common to incorporate the patient perspective into drug development and regulatory decision making. Objective: This study aimed to measure and quantify patient preferences (priorities and trade-offs) for attributes that characterize current and emerging refractory chronic spontaneous urticaria (rCSU) treatments. Methods: Adult patients with self-reported rCSU symptoms completed an online discrete choice experiment survey. The survey included 10 questions that asked respondents to choose between 2 hypothetical rCSU treatment profiles having similar attributes with varying levels. The attributes included the following: chance of control of symptoms, time to symptom control, return of symptoms after discontinuation of therapy (complete remission), allergic reaction, risk of kidney dysfunction (usually reversible), and mode and frequency of administration. Relative attribute importance and maximum acceptable risks were calculated. Results: A total of 213 subjects with a mean age of 51 years completed the survey. Efficacy (symptom control) and mode of administration were the 2 most important attributes to treatment choice, followed by risk of kidney dysfunction and time to achieve symptom control. Complete remission of symptoms and risk of allergic reaction were identified as least important. With regard to mode of administration, topical treatment was the most preferred option and infusion therapy was least preferred. Respondents who were presented with a scenario of refractory and severe chronic spontaneous urticaria were willing to accept increased risk of reversible kidney dysfunction in exchange for improvement in symptom control or complete remission. Respondents were willing to accept infusion over topical treatment if there was significant increase in treatment efficacy. Conclusion: These study results can be used to inform development and evaluation of future rCSU therapies by product developers and regulatory authorities, respectively.http://www.sciencedirect.com/science/article/pii/S2772829325000694Patient preferencediscrete choice experimentrefractory chronic urticariabenefit-risktrade-offproduct development |
| spellingShingle | Olufemi Babalola, MHS, MSc, PhD Richard Hass, PhD John McAna, PhD Manav Segal, MD Juan Marcos Gonzalez, PhD Olajumoke Fadugba, MD Quantifying patient preferences for treatments for refractory chronic spontaneous urticaria Journal of Allergy and Clinical Immunology: Global Patient preference discrete choice experiment refractory chronic urticaria benefit-risk trade-off product development |
| title | Quantifying patient preferences for treatments for refractory chronic spontaneous urticaria |
| title_full | Quantifying patient preferences for treatments for refractory chronic spontaneous urticaria |
| title_fullStr | Quantifying patient preferences for treatments for refractory chronic spontaneous urticaria |
| title_full_unstemmed | Quantifying patient preferences for treatments for refractory chronic spontaneous urticaria |
| title_short | Quantifying patient preferences for treatments for refractory chronic spontaneous urticaria |
| title_sort | quantifying patient preferences for treatments for refractory chronic spontaneous urticaria |
| topic | Patient preference discrete choice experiment refractory chronic urticaria benefit-risk trade-off product development |
| url | http://www.sciencedirect.com/science/article/pii/S2772829325000694 |
| work_keys_str_mv | AT olufemibabalolamhsmscphd quantifyingpatientpreferencesfortreatmentsforrefractorychronicspontaneousurticaria AT richardhassphd quantifyingpatientpreferencesfortreatmentsforrefractorychronicspontaneousurticaria AT johnmcanaphd quantifyingpatientpreferencesfortreatmentsforrefractorychronicspontaneousurticaria AT manavsegalmd quantifyingpatientpreferencesfortreatmentsforrefractorychronicspontaneousurticaria AT juanmarcosgonzalezphd quantifyingpatientpreferencesfortreatmentsforrefractorychronicspontaneousurticaria AT olajumokefadugbamd quantifyingpatientpreferencesfortreatmentsforrefractorychronicspontaneousurticaria |